Oligodendrocyte development and myelination in neurodevelopment: Molecular mechanisms in health and disease

Current Pharmaceutical Design

Volumn 22, Issue 6, 2016, Pages 656-679

  Barateiro, Andreia ^a   Brites, Dora ^a,b   Fernandes, Adelaide ^a,b  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

Alzheimer s disease; Hyperbilirubinemia; Hypoxia ischemia; Multiple sclerosis; Oligodendrocyte development and myelination regulation; Oligodendrocyte injury; Periventricular leukomalacia; Schizophrenia

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; GROWTH FACTOR; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; TRANSCRIPTION FACTOR;

ALZHEIMER DISEASE; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CYTOSKELETON; DEGENERATIVE DISEASE; ENDOPLASMIC RETICULUM STRESS; EXCITOTOXICITY; HUMAN; HYPERBILIRUBINEMIA; HYPOXIA; INFLAMMATION; INTRACELLULAR SIGNALING; ISCHEMIA; LEUKOMALACIA; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELINATION; NEONATAL HYPERBILIRUBINEMIA; NERVE CELL; NERVE CELL DIFFERENTIATION; NEUROLOGIC DISEASE; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY MECHANISM; SCHIZOPHRENIA; STEM CELL; ANIMAL; CELL COMMUNICATION; CELL LINEAGE; CENTRAL NERVOUS SYSTEM DISEASE; CYTOLOGY; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; METABOLISM; NERVOUS SYSTEM; PATHOLOGY;

ANIMALS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL LINEAGE; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MYELIN SHEATH; NERVOUS SYSTEM; NEURONS; OLIGODENDROGLIA;

EID: 84958232730     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151204000636     Document Type: Article

References (479)

1. Barateiro A, Fernandes A. Temporal oligodendrocyte lineage progression: in vitro models of proliferation, differentiation and mye- lination. Biochim Biophys Acta 2014; 1843: 1917-29.
2. Back SA, Rosenberg PA. Pathophysiology of glia in perinatal white matter injury. Glia 2014; 62(11): 1790-815.
3. Rees S, Inder T. Fetal and neonatal origins of altered brain development. Early Hum Dev 2005; 81: 753-61.
4. Brites D, Fernandes A. Bilirubininduced neural impairment: a special focus on myelination, age-related windows of susceptibility and associated co-morbidities. Semin Fetal Neonatal Med 2015; 20: 14-9.
5. Brites D, Bhutani V. In Cerebral Palsy, Margaret Mayston Bernard Dan, Nigel Paneth and Lewis Rosenbloom, ed.; Mac Keith Press: London 2014; pp 131-150.
6. Koch K, Schultz CC, Wagner G, et al. Disrupted white matter connectivity is associated with reduced cortical thickness in the cingulate cortex in schizophrenia. Cortex 2013; 49: 722-9.
7. Jessell TM. Neuronal specification in the spinal cord: inductive signals and transcriptional codes. Nat Rev Genet 2000; 1: 20-9.
8. Marquardt T, Pfaff SL. Cracking the transcriptional code for cell specification in the neural tube. Cell 2001; 106: 651-4.
9. Kessaris N, Pringle N, Richardson WD. Ventral neurogenesis and the neuronglial switch. Neuron 2001; 31: 677-80.
10. Rowitch DH. Glial specification in the vertebrate neural tube. Nat Rev Neurosci 2004; 5: 409-19.
11. Lu QR; Sun T; Zhu Z, et al. Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell 2002; 109: 75-86.
12. Takebayashi H, Nabeshima Y, Yoshida S, Chisaka O, Ikenaka K.The basic helix-loop-helix factor olig2 is essential for the development of motoneuron and oligodendrocyte lineages. Curr Biol 2002; 12: 1157-63.
13. Dessaud E, McMahon AP, Briscoe J. Pattern formation in the ver-tebrate neural tube: a sonic hedgehog morphogen-regulated transcriptional network. Development 2008; 135: 2489-503.
14. Hall A, Giese NA, Richardson WD. Spinal cord oligodendrocytes develop from ventrally derived progenitor cells that express PDGF alpha-receptors. Development 1996; 122: 4085-94.
15. Warf BC, Fok-Seang J, Miller RH. Evidence for the ventral origin of oligodendrocyte precursors in the rat spinal cord. J Neurosci 1991; 11: 2477-88.
16. Cai J, Qi Y, Hu X, et al. Generation of oligodendrocyte precursor cells from mouse dorsal spinal cord independent of Nkx6 regulation and Shh signaling. Neuron 2005; 45: 41-53.
17. Fogarty M, Richardson WD, Kessaris N. A subset of oligodendro-cytes generated from radial glia in the dorsal spinal cord. Devel- opment 2005; 132: 1951-9.
18. Kessaris N, Fogarty M, Iannarelli P, Grist M, Wegner M, Richardson WD. Competing waves of oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage. Nat Neurosci 2006; 9: 173-9.
19. Spassky N; Olivier C; Cobos I, et al. The early steps of oligoden-drogenesis: insights from the study of the plp lineage in the brain of chicks and rodents. Dev Neurosci 2001; 23: 318-26.
20. Tekki-Kessaris N, Woodruff R, Hall AC, et al. Hedgehog-dependent oligodendrocyte lineage specification in the telencephalon. Development 2001; 128: 2545-54.
21. Tsai HH, Frost E, To V, et al. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 2002; 110: 373-83.
22. Tsai HH, Tessier-Lavigne M, Miller RH. Netrin 1 mediates spinal cord oligodendrocyte precursor dispersal. Development 2003; 130: 2095-105.
23. Tripathi RB, Clarke LE, Burzomato V, et al. Dorsally and ventrally derived oligodendrocytes have similar electrical properties but myelinate preferred tracts. J Neurosci 2011; 31: 6809-19.
24. Dimou L, Simon C, Kirchhoff F, Takebayashi H, Gotz M. Progeny of Olig2-expressing progenitors in the gray and white matter of the adult mouse cerebral cortex. J Neurosci 2008; 28: 10434-42.
25. Rivers LE, Young KM, Rizzi M, et al. PDGFRA/NG2 glia gener-ate myelinating oligodendrocytes and piriform projection neurons in adult mice. Nat Neurosci 2008; 11: 1392-401.
26. Nishiyama A, Lin XH, Giese N, Heldin CH, Stallcup WB. Interac-tion between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. J Neuro- sci Res 1996; 43: 315-30.
27. Pringle NP, Mudhar HS, Collarini EJ, Richardson WD. PDGF receptors in the rat CNS: during late neurogenesis, PDGF alphareceptor expression appears to be restricted to glial cells of the oli- godendrocyte lineage. Development 1992; 115: 535-51.
28. Grinspan JB, Franceschini B. Platelet-derived growth factor is a survival factor for PSA-NCAM+ oligodendrocyte pre-progenitor cells. J Neurosci Res 1995; 41: 540-51.
29. Sharifi K, Ebrahimi M, Kagawa Y, et al. Differential expression and regulatory roles of FABP5 and FABP7 in oligodendrocyte lineage cells. Cell Tissue Res 2013; 354: 683-95.
30. Chittajallu R, Aguirre A, Gallo V. NG2-positive cells in the mouse white and grey matter display distinct physiological properties. J Physiol 2004; 561: 109-22.
31. Gallo V, Mangin JM, Kukley M, Dietrich D. Synapses on NG2-expressing progenitors in the brain: multiple functions? J Physiol 2008; 586: 3767-81.
32. Kukley M, Nishiyama A, Dietrich D. The fate of synaptic input to NG2 glial cells: neurons specifically downregulate transmitter re- lease onto differentiating oligodendroglial cells. J Neurosci 2010; 30: 8320-31.
33. Sommer I, Schachner M. Monoclonal antibodies (O1 to O4) to oligodendrocyte cell surfaces: an immunocytological study in the central nervous system. Dev Biol 1981; 83: 311-27.
34. Boda E, Vigano F, Rosa P, et al. The GPR17 receptor in NG2 expressing cells: focus on in vivo cell maturation and participation in acute trauma and chronic damage. Glia 2011; 59: 1958-73.
35. Yu WP, Collarini EJ, Pringle NP, Richardson WD. Embryonic expression of myelin genes: evidence for a focal source of oligodendrocyte precursors in the ventricular zone of the neural tube. Neuron 1994; 12: 1353-62.
36. Gard AL, Pfeiffer SE. Oligodendrocyte progenitors isolated di-rectly from developing telencephalon at a specific phenotypic stage: myelinogenic potential in a defined environment. Development 1989; 106: 119-32.
37. Reynolds R, Wilkin GP. Development of macroglial cells in rat cerebellum. II. An in situ immunohistochemical study of oligodendroglial lineage from precursor to mature myelinating cell. Development 1988; 102: 409-25.
38. Scolding NJ, Frith S, Linington C, Morgan BP, Campbell AK, Compston DA. Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation. J Neuroimmunol 1989; 22: 169-76.
39. Zhang SC. Defining glial cells during CNS development. Nat Rev Neurosci 2001; 2: 840-3.
40. Koenning M, Jackson S, Hay CM, et al. Myelin gene regulatory factor is required for maintenance of myelin and mature oligodendrocyte identity in the adult CNS. J Neurosci 2012; 32: 12528-42.
41. Wang SZ, Dulin J, Wu H, et al. An oligodendrocyte-specific zincfinger transcription regulator cooperates with Olig2 to promote oligodendrocyte differentiation. Development 2006; 133: 3389-98.
42. Jakovcevski I, Filipovic R, Mo Z, Rakic S, Zecevic N. Oligoden-drocyte development and the onset of myelination in the human fetal brain. Front Neuroanat 2009; 3: 5.
43. Back SA, Luo NL, Borenstein NS, Levine JM, Volpe JJ, Kinney HC. Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury. J Neurosci 2001; 21: 1302-12.
44. Craig A, Ling Luo N, Beardsley DJ, et al. Quantitative analysis of perinatal rodent oligodendrocyte lineage progression and its correlation with human. Exp Neurol 2003; 181: 231-40.
45. Huppi PS, Warfield S, Kikinis R, et al. Quantitative magnetic reso-nance imaging of brain development in premature and mature newborns. Ann Neurol 1998; 43: 224-35.
46. Timsit S, Martinez S, Allinquant B, Peyron F, Puelles L, Zalc B. Oligodendrocytes originate in a restricted zone of the embryonic ventral neural tube defined by DM-20 mRNA expression. J Neurosci 1995; 15: 1012-24.
47. Birling MC, Price J. A study of the potential of the embryonic rat telencephalon to generate oligodendrocytes. Dev Biol 1998; 193: 100-13.
48. Dean JM, Moravec MD, Grafe M, et al. Strain-specific differences in perinatal rodent oligodendrocyte lineage progression and its correlation with human. Dev Neurosci 2011; 33: 251-60.
49. Craig A, Ling Luo N, Beardsley DJ, et al. Quantitative analysis of perinatal rodent oligodendrocyte lineage progression and its correlation with human. Exp Neurol 2003; 181: 231-40.
50. Bjelke B, Seiger A. Morphological distribution of MBP-like im-munoreactivity in the brain during development. Int J Dev Neurosci 1989; 7: 145-64.
51. Hardy RJ, Friedrich VL, Jr. Progressive remodeling of the oli-godendrocyte process arbor during myelinogenesis. Dev Neurosci 1996; 18: 243-54.
52. Hartman BK, Agrawal HC, Kalmbach S, Shearer WT. A compara-tive study of the immunohistochemical localization of basic protein to myelin and oligodendrocytes in rat and chicken brain. J Comp Neurol 1979; 188: 273-90.
53. Back SA. Recent advances in human perinatal white matter injury. Prog Brain Res 2001; 132: 131-47.
54. Liu Z, Hu X, Cai J, et al. Induction of oligodendrocyte differentiation by Olig2 and Sox10: evidence for reciprocal interactions and dosage-dependent mechanisms. Dev Biol 2007; 302: 683-93.
55. Stolt CC, Lommes P, Friedrich RP, Wegner M. Transcription factors Sox8 and Sox10 perform non-equivalent roles during oligodendrocyte development despite functional redundancy. Development 2004; 131: 2349-58.
56. Woodruff RH, Tekki-Kessaris N, Stiles CD, Rowitch DH, Richardson WD. Oligodendrocyte development in the spinal cord and telencephalon: common themes and new perspectives. Int J Dev Neurosci 2001; 19: 379-85.
57. Copray S, Balasubramaniyan V, Levenga J, de Bruijn J, Liem R, Boddeke E. Olig2 overexpression induces the in vitro differentiation of neural stem cells into mature oligodendrocytes. Stem Cells 2006; 24: 1001-10.
58. Buffo A, Vosko MR, Erturk D, et al. Expression pattern of thetranscription factor Olig2 in response to brain injuries: implications for neuronal repair. Proc Natl Acad Sci USA 2005; 102: 18183-8.
59. Xin M, Yue T, Ma Z, Wu FF, Gow A, Lu QR. Myelinogenesis and axonal recognition by oligodendrocytes in brain are uncoupled in Olig1-null mice. J Neurosci 2005; 25: 1354-65.
60. Arnett HA, Fancy SP, Alberta JA, et al. bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS. Science 2004; 306: 2111-5.
61. Paes de Faria J, Kessaris N, Andrew P, Richardson WD, Li H. New Olig1 null mice confirm a non-essential role for Olig1 in oligodendrocyte development. BMC Neurosci 2014; 15: 12.
62. Xin M, Yue T, Ma Z, Wu FF, Gow A, Lu QR. Myelinogenesis and axonal recognition by oligodendrocytes in brain are uncoupled in Olig1-null mice. J Neurosci 2005; 25: 1354-65.
63. Lunn KF, Baas PW, Duncan ID. Microtubule organization and stability in the oligodendrocyte. J Neurosci 1997; 17: 4921-32.
64. Simpson PB, Armstrong RC. Intracellular signals and cytoskeletal elements involved in oligodendrocyte progenitor migration. Glia 1999; 26: 22-35.
65. Terada N, Kidd GJ, Kinter M, Bjartmar C, Moran-Jones K, Trapp BD. Beta IV tubulin is selectively expressed by oligodendrocytes in the central nervous system. Glia 2005; 50: 212-22.
66. Song J, Goetz BD, Baas PW, Duncan ID. Cytoskeletal reorganiza-tion during the formation of oligodendrocyte processes and branches. Mol Cell Neurosci 2001; 17: 624-36.
67. Li W, Zhang B, Tang J, et al. Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating alpha-tubulin. J Neurosci 2007; 27: 2606-16.
68. Pollard TD. Regulation of actin filament assembly by Arp2/3 com-plex and formins. Annu Rev Biophys Biomol Struct 2007; 36: 451-77.
69. Weaver AM, Young ME, Lee WL, Cooper JA. Integration of sig- nals to the Arp2/3 complex. Curr Opin Cell Biol 2003; 15: 23-30.
70. Bretschneider T, Diez S, Anderson K, et al. Dynamic actin patterns and Arp2/3 assembly at the substrate-attached surface of motile cells. Curr Biol 2004; 14: 1-10.
71. Svitkina TM, Borisy GG. Arp2/3 complex and actin depolymeriz-ing factor/cofilin in dendritic organization and treadmilling of actin filament array in lamellipodia. J Cell Biol 1999; 145: 1009-26.
72. Bacon C, Lakics V, Machesky L, Rumsby M. N-WASP regulatesextension of filopodia and processes by oligodendrocyte progeni- tors, oligodendrocytes, and Schwann cells-implications for axon ensheathment at myelination. Glia 2007; 55: 844-58.
73. Sloane JA, Vartanian TK. WAVE1 and regulation of actin nuclea-tion in myelination. Neuroscientist 2007; 13: 486-91.
74. Begum R, Nur EKMS, Zaman MA. The role of Rho GTPases in the regulation of the rearrangement of actin cytoskeleton and cell movement. Exp Mol Med 2004; 36: 358-66.
75. Stradal TE, Rottner K, Disanza A, Confalonieri S, Innocenti M, Scita G. Regulation of actin dynamics by WASP and WAVE family proteins. Trends Cell Biol 2004; 14: 303-11.
76. Liang X, Draghi NA, Resh MD. Signaling from integrins to Fyn to Rho family GTPases regulates morphologic differentiation of oligodendrocytes. J Neurosci 2004; 24: 7140-9.
77. Maekawa M, Ishizaki T, Boku S, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999; 285: 895-8.
78. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 2000; 261: 44-51.
79. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behav-iour. Nat Rev Mol Cell Biol 2003; 4: 446-56.
80. Pedraza CE, Taylor C, Pereira A, et al. Induction of oligodendro-cyte differentiation and in vitro myelination by inhibition of rho- associated kinase. ASN Neuro 2014; 6.
81. Derivery E, Gautreau A. Assaying WAVE and WASH complex constitutive activities toward the Arp2/3 complex. Methods Enzymol 2010; 484: 677-95.
82. Kempiak SJ, Yamaguchi H, Sarmiento C, et al. A neural Wiskott-Aldrich Syndrome protein-mediated pathway for localized activa- tion of actin polymerization that is regulated by cortactin. J Biol Chem 2005; 280: 5836-42.
83. Kim HJ, DiBernardo AB, Sloane JA, et al. WAVE1 is required for oligodendrocyte morphogenesis and normal CNS myelination. J Neurosci 2006; 26: 5849-59.
84. Barres BA, Lazar MA, Raff MC. A novel role for thyroid hormone,glucocorticoids and retinoic acid in timing oligodendrocyte development. Development 1994; 120: 1097-108.
85. Baron W, Colognato H, ffrench-Constant C. Integrin-growth factor interactions as regulators of oligodendroglial development and function. Glia 2005; 49: 467-79.
86. Miller RH. Regulation of oligodendrocyte development in the vertebrate CNS. Prog Neurobiol 2002; 67: 451-67.
87. Noble M, Murray K, Stroobant P, Waterfield MD, Riddle P. Plate-let-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. Nature 1988; 333: 560-2.
88. Raff MC, Lillien LE, Richardson WD, Burne JF, Noble MD. Plate-let-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature 1988; 333: 562-5.
89. Richardson WD, Pringle N, Mosley MJ, Westermark B, Dubois-Dalcq M. A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Cell 1988; 53: 309-19.
90. Tang DG, Tokumoto YM, Apperly JA, Lloyd AC, Raff MC. Lack of replicative senescence in cultured rat oligodendrocyte precursor cells. Science 2001; 291: 868-71.
91. Hill RA, Patel KD, Medved J, Reiss AM, Nishiyama A. NG2 cells in white matter but not gray matter proliferate in response to PDGF. J Neurosci 2013; 33: 14558-66.
92. Bansal R, Pfeiffer SE. Inhibition of protein and lipid sulfation in oligodendrocytes blocks biological responses to FGF-2 and retards cytoarchitectural maturation, but not developmental lineage pro- gression. Dev Biol 1994; 162: 511-24.
93. McKinnon RD, Matsui T, Dubois-Dalcq M, Aaronson SA. FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 1990; 5: 603-14.
94. Fressinaud C, Vallat JM, Labourdette G. Basic fibroblast growth factor down-regulates myelin basic protein gene expression and alters myelin compaction of mature oligodendrocytes in vitro. J Neurosci Res 1995; 40: 285-93.
95. Goddard DR, Berry M, Kirvell SL, Butt AM. Fibroblast growth factor-2 inhibits myelin production by oligodendrocytes in vivo. Mol Cell Neurosci 2001; 18: 557-69.
96. Bogler O, Wren D, Barnett SC, Land H, Noble M. Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. Proc Natl Acad Sci USA 1990; 87: 6368-72.
97. Jiang F, Frederick TJ, Wood TL. IGF-I synergizes with FGF-2 to stimulate oligodendrocyte progenitor entry into the cell cycle. Dev Biol 2001; 232: 414-23.
98. McMorris FA, Furlanetto RW, Mozell RL, Carson MJ, Raible DW. Regulation of oligodendrocyte development by insulin-like growth factors and cyclic nucleotides. Ann N Y Acad Sci 1990; 605: 101-9.
99. Cruz-Martinez P, Martinez-Ferre A, Jaramillo-Merchan J, Estirado A, Martinez S, Jones J. FGF8 activates proliferation and migration in mouse post-natal oligodendrocyte progenitor cells. PLoS One 2014; 9: e108241.
100. Fortin D, Rom E, Sun H, Yayon A, Bansal R. Distinct fibroblast growth factor (FGF)/FGF receptor signaling pairs initiate diverse cellular responses in the oligodendrocyte lineage. J Neurosci 2005; 25: 7470-9.
101. Kumar S, Kahn MA, Dinh L, de Vellis J. NT-3-mediated TrkC receptor activation promotes proliferation and cell survival of rodent progenitor oligodendrocyte cells in vitro and in vivo. J Neuro- sci Res 1998; 54: 754-65.
102. McTigue DM, Horner PJ, Stokes BT, Gage FH. Neurotrophin-3and brain-derived neurotrophic factor induce oligodendrocyte pro- liferation and myelination of regenerating axons in the contused adult rat spinal cord. J Neurosci 1998; 18: 5354-65.
103. Yan H, Wood PM. NT-3 weakly stimulates proliferation of adult rat O1(-)O4(+) oligodendrocyte-lineage cells and increases oligodendrocyte myelination in vitro. J Neurosci Res 2000; 62: 329-35.
104. Baas D, Bourbeau D, Sarlieve LL, Ittel ME, Dussault JH, Puymirat J. Oligodendrocyte maturation and progenitor cell proliferation are independently regulated by thyroid hormone. Glia 1997; 19: 324-32.
105. Almazan G, Honegger P, Matthieu JM. Triiodothyronine stimula-tion of oligodendroglial differentiation and myelination. A developmental study. Dev Neurosci 1985; 7: 45-54.
106. Calza L, Fernandez M, Giuliani A, Aloe L, Giardino L. Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Proc Natl Acad Sci USA 2002; 99: 3258-63.
107. Dussault JH, Ruel J. Thyroid hormones and brain development.Annu Rev Physiol 1987; 49: 321-34.
108. Walters SN, Morell P. Effects of altered thyroid states on myelino-genesis. J Neurochem 1981; 36: 1792-801.
109. Baas D, Legrand C, Samarut J, Flamant F. Persistence of oligoden-drocyte precursor cells and altered myelination in optic nerve associated to retina degeneration in mice devoid of all thyroid hormone receptors. Proc Natl Acad Sci USA 2002; 99: 2907-11.
110. Baxi EG, Schott JT, Fairchild AN, et al. A selective thyroid hor-mone beta receptor agonist enhances human and rodent oligodendrocyte differentiation. Glia 2014; 62: 1513-29.
111. Marziali LN, Garcia CI, Pasquini JM. Transferrin and thyroid hor-mone converge in the control of myelinogenesis. Exp Neurol 2015; 265: 129-41.
112. Chang MY, Son H, Lee YS, Lee SH. Neurons and astrocytes se-crete factors that cause stem cells to differentiate into neurons and astrocytes, respectively. Mol Cell Neurosci 2003; 23: 414-26.
113. Miyagi M, Mikawa S, Sato T, et al. BMP2, BMP4, noggin,BMPRIA, BMPRIB, and BMPRII are differentially expressed in the adult rat spinal cord. Neuroscience 2012; 203: 12-26.
114. See J; Zhang X; Eraydin N, et al. Oligodendrocyte maturation isinhibited by bone morphogenetic protein. Mol Cell Neurosci 2004; 26: 481-92.
115. See JM, Grinspan JB. Sending mixed signals: bone morphogenetic protein in myelination and demyelination. J Neuropathol Exp Neurol 2009; 68: 595-604.
116. Mayer M, Bhakoo K, Noble M. Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. Development 1994; 120: 143-53.
117. McKinnon RD, Piras G, Ida JA, Jr., Dubois-Dalcq M. A role for TGF-beta in oligodendrocyte differentiation. J Cell Biol 1993; 121: 1397-407.
118. Valerio A, Ferrario M, Dreano M, Garotta G, Spano P, Pizzi M.Soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro differentiation of purified rat oligodendroglial lineage cells. Mol Cell Neurosci 2002; 21: 602-15.
119. Vela JM, Molina-Holgado E, Arevalo-Martin A, Almazan G, Guaza C. Interleukin-1 regulates proliferation and differentiation of oligodendrocyte progenitor cells. Mol Cell Neurosci 2002; 20: 489-502.
120. Baerwald KD, Popko B. Developing and mature oligodendrocytes respond differently to the immune cytokine interferon-gamma. J Neurosci Res 1998; 52: 230-9.
121. Chew LJ, King WC, Kennedy A, Gallo V. Interferon-gamma inhib-its cell cycle exit in differentiating oligodendrocyte progenitor cells. Glia 2005; 52: 127-43.
122. Deverman BE, Patterson PH. Exogenous leukemia inhibitory factorstimulates oligodendrocyte progenitor cell proliferation and en- hances hippocampal remyelination. J Neurosci 2012; 32: 2100-9.
123. Ishibashi T, Dakin KA, Stevens B, et al. Astrocytes promote myelination in response to electrical impulses. Neuron 2006; 49: 823-32.
124. Fischer R, Wajant H, Kontermann R, Pfizenmaier K, Maier O. Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor. Glia 2014; 62: 272-83.
125. Palazuelos J, Klingener M, Aguirre A. TGFbeta signaling regulatesthe timing of CNS myelination by modulating oligodendrocyte progenitor cell cycle exit through SMAD3/4/FoxO1/Sp1. J Neuro- sci 2014; 34: 7917-30.
126. Rodgers JM, Robinson AP, Rosler ES, et al. IL-17A activatesERK1/2 and enhances differentiation of oligodendrocyte progenitor cells. Glia 2015; 63(5): 768-79.
127. Kadi L, Selvaraju R, de Lys P, Proudfoot AE, Wells TN, Boschert U. Differential effects of chemokines on oligodendrocyte precursor proliferation and myelin formation in vitro. J Neuroimmunol 2006; 174: 133-46.
128. Robinson S, Tani M, Strieter RM, Ransohoff RM, Miller RH. The chemokine growth-regulated oncogene-alpha promotes spinal cord oligodendrocyte precursor proliferation. J Neurosci 1998; 18: 10457-63.
129. Voyvodic JT. Target size regulates calibre and myelination of sympathetic axons. Nature 1989; 342: 430-3.
130. Simons M, Trajkovic K. Neuron-glia communication in the control of oligodendrocyte function and myelin biogenesis. J Cell Sci 2006; 119: 4381-9.
131. Gibson EM, Purger D, Mount CW, et al. Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mam-malian brain. Science 2014; 344: 1252304.
132. Bakiri Y, Burzomato V, Frugier G, Hamilton NB, Karadottir R, Attwell D. Glutamatergic signaling in the brain's white matter.Neuroscience 2009; 158: 266-74.
133. Butt AM. Neurotransmitter-mediated calcium signalling in oli- godendrocyte physiology and pathology. Glia 2006; 54: 666-75.
134. Karadottir R, Attwell D. Neurotransmitter receptors in the life and death of oligodendrocytes. Neuroscience 2007; 145: 1426-38.
135. Li S, Stys PK. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter. J Neurosci 2000; 20: 1190-8.
136. Itoh T, Beesley J, Itoh A, et al. AMPA glutamate receptor- mediated calcium signaling is transiently enhanced during development of oligodendrocytes. J Neurochem 2002; 81: 390-402.
137. Deng W, Rosenberg PA, Volpe JJ, Jensen FE. Calcium-permeable AMPA/kainate receptors mediate toxicity and preconditioning by oxygen-glucose deprivation in oligodendrocyte precursors. Proc Natl Acad Sci USA 2003; 100: 6801-6.
138. Rosenberg PA, Dai W, Gan XD, et al. Mature myelin basic pro- tein-expressing oligodendrocytes are insensitive to kainate toxicity.J Neurosci Res 2003; 71: 237-45.
139. Karadottir R, Cavelier P, Bergersen LH, Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005; 438: 1162-6.
140. Patneau DK, Wright PW, Winters C, Mayer ML, Gallo V. Glial cells of the oligodendrocyte lineage express both kainateand AMPA-preferring subtypes of glutamate receptor. Neuron 1994; 12: 357-71.
141. Li C, Xiao L, Liu X, et al. A functional role of NMDA receptor in regulating the differentiation of oligodendrocyte precursor cells and remyelination. Glia 2013; 61: 732-49.
142. Cavaliere F, Benito-Munoz M, Panicker M, Matute C. NMDA modulates oligodendrocyte differentiation of subventricular zone cells through PKC activation. Front Cell Neurosci 2013; 7: 261.
143. De Biase LM, Kang SH, Baxi EG, et al. NMDA receptor signaling in oligodendrocyte progenitors is not required for oligodendrogenesis and myelination. J Neurosci 2011; 31: 12650-62.
144. Guo F, Maeda Y, Ko EM, et al. Disruption of NMDA receptors in oligodendroglial lineage cells does not alter their susceptibility to experimental autoimmune encephalomyelitis or their normal development. J Neurosci 2012; 32: 639-45.
145. Lundgaard I, Luzhynskaya A, Stockley JH, et al. Neuregulin and BDNF induce a switch to NMDA receptor-dependent myelination by oligodendrocytes. PLoS Biol 2013; 11: e1001743.
146. Stevens B, Porta S, Haak LL, Gallo V, Fields RD. Adenosine: a neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron 2002; 36: 855-68.
147. Pastor A, Chvatal A, Sykova E, Kettenmann H. Glycine and GABA-activated currents in identified glial cells of the developing rat spinal cord slice. Eur J Neurosci 1995; 7: 1188-98.
148. Williamson AV, Mellor JR, Grant AL, Randall AD. Properties of GABA(A) receptors in cultured rat oligodendrocyte progenitor cells. Neuropharmacology 1998; 37: 859-73.
149. Lin SC, Bergles DE. Synaptic signaling between GABAergic in-terneurons and oligodendrocyte precursor cells in the hippocampus. Nat Neurosci 2004; 7: 24-32.
150. Soliven B. Calcium signalling in cells of oligodendroglial lineage. Microsc Res Tech 2001; 52: 672-9.
151. Yoo AS, Krieger C, Kim SU. Process extension and intracellularCa2+ in cultured murine oligodendrocytes. Brain Res 1999; 827: 19-27.
152. Paez PM, Spreuer V, Handley V, Feng JM, Campagnoni C, Cam-pagnoni AT. Increased expression of golli myelin basic proteins enhances calcium influx into oligodendroglial cells. J Neurosci 2007; 27: 12690-9.
153. Paez PM, Fulton DJ, Spreuer V, et al. Golli myelin basic proteins regulate oligodendroglial progenitor cell migration through volt- age-gated Ca2+ influx. J Neurosci 2009; 29: 6663-76.
154. Cheli VT, Santiago Gonzalez DA, Spreuer V, Paez PM. Voltage-gated Ca(++) entry promotes oligodendrocyte progenitor cell maturation and myelination in vitro. Exp Neurol 2015; 265: 69-83.
155. Garthwaite G, Hampden-Smith K, Wilson GW, Goodwin DA, Garthwaite J. Nitric oxide targets oligodendrocytes and promotes their morphological differentiation. Glia 2015; 63: 383-99.
156. Doherty P, Walsh FS. CAM-FGF Receptor Interactions: A Model for Axonal Growth. Mol Cell Neurosci 1996; 8: 99-111.
157. Charles P, Hernandez MP, Stankoff B, et al. Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule. Proc Natl Acad Sci USA 2000; 97: 7585-90.
158. Theodosis DT, El Majdoubi M, Pierre K, Poulain DA. Factors governing activity-dependent structural plasticity of the hypo- thalamoneurohypophysial system. Cell Mol Neurobiol 1998; 18: 285-98.
159. Seki T, Arai Y. Distribution and possible roles of the highly poly-sialylated neural cell adhesion molecule (NCAM-H) in the developing and adult central nervous system. Neurosci Res 1993; 17: 265-90.
160. Seki T, Arai Y. The persistent expression of a highly polysialylated NCAM in the dentate gyrus of the adult rat. Neurosci Res 1991; 12: 503-13.
161. Kiss JZ, Wang C, Olive S, et al. Activity-dependent mobilization of the adhesion molecule polysialic NCAM to the cell surface of neurons and endocrine cells. Embo J 1994; 13: 5284-92.
162. Landmesser L, Dahm L, Tang JC, Rutishauser U. Polysialic acid as a regulator of intramuscular nerve branching during embryonic development. Neuron 1990; 4: 655-67.
163. Decker L, Avellana-Adalid V, Nait-Oumesmar B, Durbec P,Baron-Van Evercooren A. Oligodendrocyte precursor migration and differentiation: combined effects of PSA residues, growth fac- tors, and substrates. Mol Cell Neurosci 2000; 16: 422-39.
164. Fewou SN, Ramakrishnan H, Bussow H, Gieselmann V, Eckhardt M. Down-regulation of polysialic acid is required for efficient myelin formation. J Biol Chem 2007; 282: 16700-11.
165. Jakovcevski I, Mo Z, Zecevic N. Down-regulation of the axonal polysialic acid-neural cell adhesion molecule expression coincides with the onset of myelination in the human fetal forebrain. Neuro- science 2007; 149: 328-37.
166. Hortsch M. The L1 family of neural cell adhesion molecules: old proteins performing new tricks. Neuron 1996; 17: 587-93.
167. Barbin G, Aigrot MS, Charles P, et al. Axonal cell-adhesion mole-cule L1 in CNS myelination. Neuron Glia Biol 2004; 1: 65-72.
168. Bourikas D, Mir A, Walmsley AR. LINGO-1-mediated inhibition of oligodendrocyte differentiation does not require the leucine-rich repeats and is reversed by p75(NTR) antagonists. Mol Cell Neurosci 2010; 45: 363-9.
169. Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates mye-lination by oligodendrocytes. Nat Neurosci 2005; 8: 745-51.
170. Yin W, Hu B. Knockdown of Lingo1b protein promotes myelina-tion and oligodendrocyte differentiation in zebrafish. Exp Neurol 2014; 251: 72-83.
171. Erschbamer MK, Hofstetter CP, Olson L. Rho A, Rho B, Rho C,Rac1, Cdc42, and Tc10 mRNA levels in spinal cord, sensory ganglia, and corticospinal tract neurons and long-lasting specific changes following spinal cord injury. J Comp Neurol 2005; 484: 224-33.
172. Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 2009; 65: 304-15.
173. Jepson S, Vought B, Gross CH, et al. LINGO-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through intercellular self-interactions. J Biol Chem 2012; 287: 22184-95.
174. Lee X, Shao Z, Sheng G, Pepinsky B, Mi S. LINGO-1 regulates oligodendrocyte differentiation by inhibiting ErbB2 translocation and activation in lipid rafts. Mol Cell Neurosci 2014; 60: 36-42.
175. Sherman DL, Brophy PJ. Mechanisms of axon ensheathment and myelin growth. Nature reviews. Neuroscience 2005; 6: 683-90.
176. Kordeli E, Lambert S, Bennett V, Ankyrin G. A new ankyrin gene with neural-specific isoforms localized at the axonal initial segment and node of Ranvier. J Biol Chem 1995; 270: 2352-9.
177. Kordeli E, Davis J, Trapp B, Bennett V. An isoform of ankyrin is localized at nodes of Ranvier in myelinated axons of central and peripheral nerves. J Cell Biol 1990; 110: 1341-52.
178. Berghs S, Aggujaro D, Dirkx R, Jr., et al. betaIV spectrin, a new spectrin localized at axon initial segments and nodes of ranvier in the central and peripheral nervous system. J Cell Biol 2000; 151: 985-1002.
179. Davis JQ, Lambert S, Bennett V. Molecular composition of the node of Ranvier: identification of ankyrin-binding cell adhesion molecules neurofascin (mucin+/third FNIII domain-) and NrCAM at nodal axon segments. J Cell biol 1996; 135: 1355-67.
180. Davis JQ, Bennett V. Ankyrin binding activity shared by the neuro-fascin/L1/NrCAM family of nervous system cell adhesion molecules. J Biol Chem 1994; 269: 27163-6.
181. Kazarinova-Noyes K, Shrager P. Molecular constituents of the node of Ranvier. Mol Neurobiol 2002; 26: 167-82.
182. Susuki K, Rasband MN. Molecular mechanisms of node of Ranvier formation. Curr Opin Cell Biol 2008; 20: 616-23.
183. Zonta B, Tait S, Melrose S, et al. Glial and neuronal isoforms of Neurofascin have distinct roles in the assembly of nodes of Ranvier in the central nervous system. J Cell Biol 2008; 181: 1169-77.
184. Rios JC, Rubin M, St Martin M, et al. Paranodal interactions regu-late expression of sodium channel subtypes and provide a diffusion barrier for the node of Ranvier. J Neurosci 2003; 23: 7001-11.
185. Kazarinova-Noyes K, Malhotra JD, McEwen DP, et al. Contactin associates with Na+ channels and increases their functional expression. J Neurosci 2001; 21: 7517-25.
186. Einheber S, Zanazzi G, Ching W, et al. The axonal membrane protein Caspr, a homologue of neurexin IV, is a component of the septate-like paranodal junctions that assemble during myelination. J Cell Biol 1997; 139: 1495-506.
187. Menegoz M, Gaspar P, Le Bert M, et al. Paranodin, a glycoprotein of neuronal paranodal membranes. Neuron 1997; 19: 319-31.
188. Charles P, Tait S, Faivre-Sarrailh C, et al. Neurofascin is a glial receptor for the paranodin/Caspr-contactin axonal complex at the axoglial junction. Curr Biol 2002; 12: 217-20.
189. Bellen HJ, Lu Y, Beckstead R, Bhat MA. Neurexin IV, caspr and paranodin--novel members of the neurexin family: encounters of axons and glia. Trends Neurosci 1998; 21: 444-9.
190. Faivre-Sarrailh C, Gauthier F, Denisenko-Nehrbass N, Le Bivic A, Rougon G, Girault JA. The glycosylphosphatidyl inositol-anchored adhesion molecule F3/contactin is required for surface transport of paranodin/contactin-associated protein (caspr). J Cell Biol 2000; 149: 491-502.
191. Gollan L, Salomon D, Salzer JL, Peles E. Caspr regulates the processing of contactin and inhibits its binding to neurofascin. J Cell Biol 2003; 163: 1213-8.
192. Gollan L, Sabanay H, Poliak S, Berglund EO, Ranscht B, Peles E.Retention of a cell adhesion complex at the paranodal junction re- quires the cytoplasmic region of Caspr. J Cell Biol 2002; 157: 1247-56.
193. Boyle ME, Berglund EO, Murai KK, Weber L, Peles E, Ranscht B.Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve. Neuron 2001; 30: 385-97.
194. Pillai AM, Thaxton C, Pribisko AL, Cheng JG, Dupree JL, Bhat MA. Spatiotemporal ablation of myelinating glia-specific neurofas- cin (Nfasc NF155) in mice reveals gradual loss of paranodal axoglial junctions and concomitant disorganization of axonal domains. J Neurosci Res 2009; 87: 1773-93.
195. Poliak S, Peles E. The local differentiation of myelinated axons at nodes of Ranvier. Nature reviews. Neuroscience 2003; 4: 968-80.
196. Vabnick I, Trimmer JS, Schwarz TL, Levinson SR, Risal D, Shrager P. Dynamic potassium channel distributions during axonal development prevent aberrant firing patterns. J Neurosci 1999; 19: 747-58.
197. Poliak S, Gollan L, Martinez R, et al. Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myeli-nated axons and associates with K+ channels. Neuron 1999; 24: 1037-47.
198. Traka M, Dupree JL, Popko B, Karagogeos D. The neuronal adhesion protein TAG-1 is expressed by Schwann cells and oligoden-drocytes and is localized to the juxtaparanodal region of myelinated fibers. J Neurosci 2002; 22: 3016-24.
199. Altevogt BM, Kleopa KA, Postma FR, Scherer SS, Paul DL. Connexin29 is uniquely distributed within myelinating glial cells of the central and peripheral nervous systems. J Neurosci 2002; 22: 6458-70.
200. Traka M, Goutebroze L, Denisenko N, et al. Association of TAG-1 with Caspr2 is essential for the molecular organization of juxta-paranodal regions of myelinated fibers. J Cell Biol 2003; 162: 1161-72.
201. Poliak S, Salomon D, Elhanany H, et al. Juxtaparanodal clustering of Shaker-like K+ channels in myelinated axons depends on Caspr2 and TAG-1. J Cell Biol 2003; 162: 1149-60.
202. Baba H, Akita H, Ishibashi T, Inoue Y, Nakahira K, Ikenaka K. Completion of myelin compaction, but not the attachment of oligodendroglial processes triggers K(+) channel clustering. J Neuro- sci Res 1999; 58: 752-64.
203. Ludwin SK. The pathobiology of the oligodendrocyte. J Neuropa-thol Exp Neurol 1997; 56: 111-24.
204. McLaurin JA, Yong VW. Oligodendrocytes and myelin. Neurol Clin 1995; 13: 23-49.
205. Matute C, Alberdi E, Domercq M, et al. Excitotoxic damage towhite matter. J Anat 2007; 210: 693-702.
206. Fern R, Moller T. Rapid ischemic cell death in immature oligoden-drocytes: a fatal glutamate release feedback loop. J Neurosci 2000; 20: 34-42.
207. Matute C. Oligodendrocyte NMDA receptors: a novel therapeutic target. Trends Mol Med 2006; 12: 289-92.
208. Verkhratsky A, Orkand RK, Kettenmann H. Glial calcium: homeo-stasis and signaling function. Physiol Rev 1998; 78: 99-141.
209. Nicholls DG, Budd SL. Mitochondria and neuronal survival. Physiol Rev 2000; 80: 315-60.
210. Zamzami N, Maisse C, Metivier D, Kroemer G. Measurement of membrane permeability and permeability transition of mitochondria. Methods Cell Biol 2001; 65: 147-58.
211. Sanchez-Gomez MV, Alberdi E, Ibarretxe G, Torre I, Matute C.Caspase-dependent and caspase-independent oligodendrocyte death mediated by AMPA and kainate receptors. J Neurosci 2003; 23: 9519-28.
212. Matute C, Torre I, Perez-Cerda F, et al. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 2007; 27: 9525-33.
213. Li J, Baud O, Vartanian T, Volpe JJ, Rosenberg PA. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc Natl Acad Sci USA 2005; 102: 9936-41.
214. Cao X, Deng X, May WS. Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax. Blood 2003; 102: 2605-14.
215. Chen M, He H, Zhan S, Krajewski S, Reed JC, Gottlieb RA. Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. J Biol Chem 2001; 276: 30724-8.
216. Villa PG, Henzel WJ, Sensenbrenner M, Henderson CE, Pettmann B. Calpain inhibitors, but not caspase inhibitors, prevent actin proteolysis and DNA fragmentation during apoptosis. J Cell Sci 1998; 111 (Pt 6): 713-22.
217. Polster BM, Basanez G, Etxebarria A, Hardwick JM, Nicholls DG. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J Biol Chem 2005; 280: 6447-54.
218. Artal-Sanz M, Tavernarakis N. Proteolytic mechanisms in necrotic cell death and neurodegeneration. FEBS Lett 2005; 579: 3287-96.
219. Yamashima T. Ca2+-dependent proteases in ischemic neuronal death: a conserved 'calpain-cathepsin cascade' from nematodes to primates. Cell Calc 2004; 36: 285-93.
220. Paszty K, Verma AK, Padanyi R, Filoteo AG, Penniston JT, Eny- edi A. Plasma membrane Ca2+ATPase isoform 4b is cleaved and activated by caspase-3 during the early phase of apoptosis. J Biol Chem 2002; 277: 6822-9.
221. Thorburne SK, Juurlink BH. Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. J Neurochem 1996; 67: 1014-22.
222. McTigue DM, Tripathi RB. The life, death, and replacement of oligodendrocytes in the adult CNS. J Neurochem 2008; 107: 19.
223. Cheepsunthorn P, Palmer C, Connor JR. Cellular distribution of ferritin subunits in postnatal rat brain. J Comp Neurol 1998; 400: 73-86.
224. Connor JR, Menzies SL. Relationship of iron to oligodendrocytes and myelination. Glia 1996; 17: 83-93.
225. Brito MA, Rosa AI, Falcao AS, et al. Unconjugated bilirubin differentially affects the redox status of neuronal and astroglial cells. Neurobiol Dis 2008; 29: 30-40.
226. Juurlink BH, Thorburne SK, Hertz L. Peroxide-scavenging deficit underlies oligodendrocyte susceptibility to oxidative stress. Glia 1998; 22: 371-8.
227. Mahad D, Lassmann H, Turnbull D. Review: Mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neuro-biol 2008; 34: 577-89.
228. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 1999; 13: 1211-33.
229. Verkhratsky A. Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol Rev 2005;85: 201-79.
230. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-29.
231. Schroder M, Kaufman RJ. The mammalian unfolded protein re-sponse. Annu Rev Biochem 2005; 74: 739-89.
232. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2000; 2: 326-32.
233. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, et al. XBP1, down- stream of Blimp-1, expands the secretory apparatus and other or-ganelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004; 21: 81-93.
234. Chen X, Shen J, Prywes R. The luminal domain of ATF6 senses endoplasmic reticulum (ER) stress and causes translocation of ATF6 from the ER to the Golgi. J Biol Chem 2002; 277: 13045-52.
235. Hong M, Li M, Mao C, Lee AS. Endoplasmic reticulum stress triggers an acute proteasome-dependent degradation of ATF6. J Cell Biochem 2004; 92: 723-32.
236. Blais JD, Filipenko V, Bi M, et al. Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol 2004;24: 7469-82.
237. Southwood CM, Garbern J, Jiang W, Gow A. The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease. Neuron 2002; 36: 585-96.
238. Sharma R, Gow A. Minimal role for caspase 12 in the unfoldedprotein response in oligodendrocytes in vivo. J Neurochem 2007; 101: 889-97.
239. Deniaud A, Sharaf el dein O, Maillier E, et al. Endoplasmic reticu-lum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. On- cogene 2008; 27: 285-99.
240. Gorlach A, Klappa P, Kietzmann T. The endoplasmic reticulum:folding, calcium homeostasis, signaling, and redox control. Anti- oxid Redox Signal 2006; 8: 1391-418.
241. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxi-dative stress: a vicious cycle or a double-edged sword? Antioxid Redox Signal 2007; 9: 2277-93.
242. Cammer W. Effects of TNFalpha on immature and mature oli-godendrocytes and their progenitors in vitro. Brain Res 2000; 864: 213-9.
243. Jurewicz A, Matysiak M, Tybor K, Kilianek L, Raine CS, Selmaj K. Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor. Brain 2005; 128: 2675-88.
244. Merrill JE, Scolding NJ. Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. Neuropathol Appl Neurobiol 1999; 25: 435-58.
245. Scurlock B, Dawson G. Differential responses of oligodendrocytes to tumor necrosis factor and other pro-apoptotic agents: role of ceramide in apoptosis. J Neurosci Res 1999; 55: 514-22.
246. Hovelmeyer N, Hao Z, Kranidioti K, et al. Apoptosis of oligoden-drocytes via Fas and TNF-R1 is a key event in the induction of experimental autoimmune encephalomyelitis. J Immunol 2005; 175: 5875-84.
247. Pang Y, Cai Z, Rhodes PG. Effect of tumor necrosis factor-alpha on developing optic nerve oligodendrocytes in culture. J Neurosci Res 2005; 80: 226-34.
248. Jenkins HG, Ikeda H. Tumour necrosis factor causes an increase in axonal transport of protein and demyelination in the mouse optic nerve. J Neurol Sci 1992; 108: 99-104.
249. Moore CS, Cui QL, Warsi NM, et al. Direct and indirect effects of immune and central nervous system-resident cells on human oli- godendrocyte progenitor cell differentiation. J Immunol 2015; 194: 761-72.
250. Horiuchi M, Itoh A, Pleasure D, Itoh T. MEK-ERK signaling is involved in interferon-gamma-induced death of oligodendroglial progenitor cells. J Biol Chem 2006; 281: 20095-106.
251. Zhang X; Haaf M; Todorich B, et al. Cytokine toxicity to oli-godendrocyte precursors is mediated by iron. Glia 2005; 52: 199-208.
252. Domercq M, Sanchez-Gomez MV, Sherwin C, Etxebarria E, Fern R, Matute C. System xc- and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes. J Immunol 2007; 178: 6549-56.
253. Li J, Ramenaden ER, Peng J, Koito H, Volpe JJ, Rosenberg PA.Tumor necrosis factor alpha mediates lipopolysaccharide-induced microglial toxicity to developing oligodendrocytes when astrocytes are present. J Neurosci 2008; 28: 5321-30.
254. Rezaie P, Dean A. Periventricular leukomalacia, inflammation and white matter lesions within the developing nervous system. Neuropathology 2002; 22: 106-32.
255. Steelman AJ, Li J. Poly(I:C) promotes TNFalpha/TNFR1-dependent oligodendrocyte death in mixed glial cultures. J Neu- roinflammation 2011; 8: 89.
256. Matute C. Calcium dyshomeostasis in white matter pathology. CellCalcium 2010; 47: 150-7.
257. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001; 50: 169-80.
258. Monif M, Reid CA, Powell KL, Smart ML, Williams DA. The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. J Neurosci 2009; 29: 3781-91.
259. Kim S, Steelman AJ, Koito H, Li J. Astrocytes promote TNF-mediated toxicity to oligodendrocyte precursors. J Neurochem 2011; 116: 53-66.
260. Nagy JI, Rash JE. Connexins and gap junctions of astrocytes and oligodendrocytes in the CNS. Brain Res Brain Res Rev 2000; 32: 29-44.
261. Orthmann-Murphy JL, Abrams CK, Scherer SS. Gap junctions couple astrocytes and oligodendrocytes. J Mol Neurosci 2008; 35: 101-16.
262. Farahani R, Pina-Benabou MH, Kyrozis A, et al. Alterations in metabolism and gap junction expression may determine the role of astrocytes as "good samaritans" or executioners. Glia 2005; 50: 351-61.
263. Froger N, Orellana JA, Calvo CF, et al. Inhibition of cytokine-induced connexin43 hemichannel activity in astrocytes is neuroprotective. Mol Cell Neurosci 2010; 45: 37-46.
264. Nair A, Frederick TJ, Miller SD. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 2008; 65: 2702-20.
265. Williams A, Piaton G, Lubetzki C. Astrocytes-friends or foes in multiple sclerosis? Glia 2007; 55: 1300-12.
266. Volpe JJ. Cerebral white matter injury of the premature infant-more common than you think. Pediatrics 2003; 112: 176-80.
267. Wilson-Costello D, Friedman H, Minich N, et al. Improved neuro- developmental outcomes for extremely low birth weight infants in 2000-2002. Pediatrics 2007; 119: 37-45.
268. Back SA, Han BH, Luo NL, et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci 2002;22: 455-63.
269. Volpe JJ. Systemic inflammation, oligodendroglial maturation, and the encephalopathy of prematurity. Ann Neurol 2011; 70: 525-9.
270. Verney C, Monier A, Fallet-Bianco C, Gressens P. Early microglial colonization of the human forebrain and possible involvement in periventricular white-matter injury of preterm infants. J Anat 2010; 217: 436-48.
271. Fatemi A, Wilson MA, Johnston MV. Hypoxic-ischemic encepha- lopathy in the term infant. Clin Perinatol 2009; 36: 835-58.
272. Verney C, Pogledic I, Biran V, Adle-Biassette H, Fallet-Bianco C, Gressens P. Microglial reaction in axonal crossroads is a hallmark of noncystic periventricular white matter injury in very preterm infants. J Neuropathol Exp Neurol 2012; 71: 251-64.
273. Larroque B, Marret S, Ancel PY, et al. White matter damage and intraventricular hemorrhage in very preterm infants: the EPIPAGE study. J Pediatrics 2003; 143: 477-83.
274. Inder TE, Warfield SK, Wang H, Huppi PS, Volpe JJ. Abnormal cerebral structure is present at term in premature infants. Pediatrics 2005; 115: 286-94.
275. Miller SP, Ferriero DM, Leonard C, et al. Early brain injury in premature newborns detected with magnetic resonance imaging is associated with adverse early neurodevelopmental outcome. J Pedi- atrics 2005; 147: 609-16.
276. Woodward LJ, Anderson PJ, Austin NC, Howard K, Inder TE. Neonatal MRI to predict neurodevelopmental outcomes in preterm infants. N Engl J Med 2006; 355: 685-94.
277. Folkerth RD, Haynes RL, Borenstein NS, et al. Developmental lag in superoxide dismutases relative to other antioxidant enzymes in premyelinated human telencephalic white matter. J Neuropathol Exp Neurol 2004; 63: 990-9.
278. Baud O, Greene AE, Li J, Wang H, Volpe JJ, Rosenberg PA. Glu-tathione peroxidase-catalase cooperativity is required for resistance to hydrogen peroxide by mature rat oligodendrocytes. J Neurosci 2004; 24: 1531-40.
279. Baud O, Haynes RF, Wang H, et al. Developmental up-regulation of MnSOD in rat oligodendrocytes confers protection against oxidative injury. Eur J Neurosci 2004; 20: 29-40.
280. Baud O, Li J, Zhang Y, Neve RL, Volpe JJ, Rosenberg PA. Nitric oxide-induced cell death in developing oligodendrocytes is associated with mitochondrial dysfunction and apoptosis-inducing factor translocation. Eur J Neurosci 2004; 20: 1713-26.
281. Haynes RL, Folkerth RD, Keefe RJ, et al. Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leu- komalacia. J Neuropathol Exp Neurol 2003; 62: 441-50.
282. Follett PL, Rosenberg PA, Volpe JJ, Jensen FE. NBQX attenuates excitotoxic injury in developing white matter. J Neurosci 2000; 20: 9235-41.
283. Itoh T, Beesley J, Itoh A, et al. AMPA glutamate receptor-mediated calcium signaling is transiently enhanced during development of oligodendrocytes. J Neurochem 2002; 81: 390-402.
284. Desilva TM, Kinney HC, Borenstein NS, et al. The glutamate transporter EAAT2 is transiently expressed in developing human cerebral white matter. J Comp Neurol 2007; 501: 879-90.
285. Back SA, Luo NL, Mallinson RA, et al. Selective vulnerability of preterm white matter to oxidative damage defined by F2- isoprostanes. Ann Neurol 2005; 58: 108-20.
286. Robinson S, Li Q, Dechant A, Cohen ML. Neonatal loss of gamma-aminobutyric acid pathway expression after human perinatal brain injury. J Neurosurg 2006; 104: 396-408.
287. Kinney HC, Back SA. Human oligodendroglial development: rela-tionship to periventricular leukomalacia. Seminars Pediatric Neurol 1998; 5: 180-9.
288. Billiards SS, Haynes RL, Folkerth RD, et al. Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia. Brain Pathol 2008; 18: 153-63.
289. Talos DM, Follett PL, Folkerth RD, et al. Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. II. Human cerebral white matter and cortex. J Comp Neurol 2006; 497: 61-77.
290. Matute C, Alberdi E, Domercq M, Perez-Cerda F, Perez-Samartin A, Sanchez-Gomez MV. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 2001; 24: 224-30.
291. Deng W, Yue Q, Rosenberg PA, Volpe JJ, Jensen FE. Oligodendrocyte excitotoxicity determined by local glutamate accumulation and mitochondrial function. J Neurochem 2006; 98: 213-22.
292. Salter MG, Fern R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 2005; 438: 1167-71.
293. Micu I, Jiang Q, Coderre E, et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 2006; 439: 988-92.
294. Billiards SS, Haynes RL, Folkerth RD, et al. Development of microglia in the cerebral white matter of the human fetus and infant. JComp Neurol 2006; 497: 199-208.
295. Haynes RL, Folkerth RD, Trachtenberg FL, Volpe JJ, Kinney HC. Nitrosative stress and inducible nitric oxide synthase expression in periventricular leukomalacia. Acta Neuropathol 2009; 118: 391-9.
296. Thornton C, Rousset CI, Kichev A, et al. Molecular mechanisms of neonatal brain injury. Neurol Res Int 2012; 2012: 506320.
297. Pantoni L, Garcia JH, Gutierrez JA. Cerebral white matter is highly vulnerable to ischemia. Stroke 1996; 27: 1641-6.
298. Tekkok SB, Goldberg MP. Ampa/kainate receptor activation mediates hypoxic oligodendrocyte death and axonal injury in cerebral white matter. J Neurosci 2001; 21: 4237-48.
299. Segovia KN, McClure M, Moravec M, et al. Arrested oligodendrocyte lineage maturation in chronic perinatal white matter injury. Ann Neurol 2008; 63: 520-30.
300. Wright J, Zhang G, Yu TS, Kernie SG. Age-related changes in the oligodendrocyte progenitor pool influence brain remodeling after injury. Dev Neurosci 2010; 32: 499-509.
301. Sizonenko SV, Camm EJ, Dayer A, Kiss JZ. Glial responses to neonatal hypoxic-ischemic injury in the rat cerebral cortex. Int J Develop Neurosci 2008; 26: 37-45.
302. Zaidi AU, Bessert DA, Ong JE, et al. New oligodendrocytes are generated after neonatal hypoxic-ischemic brain injury in rodents. Glia 2004; 46: 380-90.
303. Yang Z, Levison SW. Hypoxia/ischemia expands the regenerative capacity of progenitors in the perinatal subventricular zone. Neuroscience 2006; 139: 555-64.
304. Deng W, Neve RL, Rosenberg PA, Volpe JJ, Jensen FE. Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subunit composition and cAMP-response element-binding protein regulate oligodendrocyte excitotoxicity. J Biol Chem 2006; 281: 36004-11.
305. Deng W, Wang H, Rosenberg PA, Volpe JJ, Jensen FE. Role of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and oxidative stress. Proc Natl Acad Sci USA 2004; 101: 7751-6.
306. Follett PL, Deng W, Dai W, et al. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J Neurosci 2004; 24: 4412-20.
307. Manning SM, Talos DM, Zhou C, et al. NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia. J Neurosci 2008; 28: 6670-8.
308. Wilke S, Thomas R, Allcock N, Fern R. Mechanism of acute ischemic injury of oligodendroglia in early myelinating white matter: the importance of astrocyte injury and glutamate release. J Neuropathol Exp Neurol 2004; 63: 872-81.
309. Oubidar M, Boquillon M, Marie C, Schreiber L, Bralet J. Ischemia-induced brain iron delocalization: effect of iron chelators. Free Radic Biol Med 1994; 16: 861-7.
310. Selim MH, Ratan RR. The role of iron neurotoxicity in ischemic stroke. Ageing Res Rev 2004; 3: 345-53.
311. Matute C, Domercq M, Sanchez-Gomez MV. Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 2006; 53: 212-24.
312. Starkov AA, Chinopoulos C, Fiskum G. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium 2004; 36: 257-64.
313. Thornton C, Hagberg H. Role of mitochondria in apoptotic and necroptotic cell death in the developing brain. Clin Chim Acta 2015.
314. Cao Y; Gunn AJ; Bennet L, et al. Insulin-like growth factor (IGF)-1 suppresses oligodendrocyte caspase-3 activation and increases glial proliferation after ischemia in near-term fetal sheep. J Cere- bral Blood Flow Metabol 2003; 23: 739-47.
315. Castillo-Melendez M, Chow JA, Walker DW. Lipid peroxidation, caspase-3 immunoreactivity, and pyknosis in late-gestation fetal sheep brain after umbilical cord occlusion. Pediatric Res 2004; 55: 864-71.
316. Riddle A; Luo NL; Manese M, et al. Spatial heterogeneity in oligodendrocyte lineage maturation and not cerebral blood flow predicts fetal ovine periventricular white matter injury. J Neurosci 2006; 26: 3045-55.
317. Domercq M, Perez-Samartin A, Aparicio D, Alberdi E, Pampliega O, Matute C. P2X7 receptors mediate ischemic damage to oligo-dendrocytes. Glia 2010; 58: 730-40.
318. Matute C. P2X7 receptors in oligodendrocytes: a novel target for neuroprotection. Mol Neurobiol 2008; 38: 123-8.
319. Matute C, Ransom BR. Roles of white matter in central nervous systemathophysiologies. ASN Neuro 2012; 4(2): piie00079.
320. Shereen A, Nemkul N, Yang D, et al. Ex vivo diffusion tensor imaging and neuropathological correlation in a murine model of hypoxia-ischemia-induced thrombotic stroke. J Cerebral Blood Flow Metabol 2011; 31: 1155-69.
321. Ichinose M, Kamei Y, Iriyama T, et al. Hypothermia attenuates apoptosis and protects contact between myelin basic protein-expressing oligodendroglial-lineage cells and neurons against hypoxia-ischemia. J Neurosci Res 2014; 92: 1270-85.
322. Jablonska B, Scafidi J, Aguirre A, et al. Oligodendrocyte regenera- tion after neonatal hypoxia requires FoxO1-mediated p27Kip1 ex-pression. J Neurosci 2012; 32: 14775-93.
323. Yuen TJ, Silbereis JC, Griveau A, et al. Oligodendrocyte-encoded HIF function couples postnatal myelination and white matter angi- ogenesis. Cell 2014; 158: 383-96.
324. Bhutani VK, Johnson LH, Keren R. Diagnosis and management of hyperbilirubinemia in the term neonate: for a safer first week. Pediatr Clin North Am 2004; 51: 843-61.
325. Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med 2008; 358: 920-8.
326. Bhutani VK, Stevenson DK. The need for technologies to prevent bilirubin-induced neurologic dysfunction syndrome. Semin Perinatol 2011; 35: 97-100.
327. Brites D. The evolving landscape of neurotoxicity by unconjugated bilirubin: role of glial cells and inflammation. Front Pharmacol 2012; 3: 88.
328. Bhutani VK. Neonatal hyperbilirubinemia and the potential risk of subtle neurological dysfunction. Pediatr Res 2001; 50: 679-80.
329. Fernandes A, Falcao AS, Abranches E, et al. Bilirubin as a deter-minant for altered neurogenesis, neuritogenesis, and synaptogene- sis. Dev Neurobiol 2009; 69: 568-82.
330. Shapiro SM. Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND). J Perinatol 2005; 25: 54-9.
331. Arun Babu T, Bhat BV, Joseph NM. Association between peak serum bilirubin and neurodevelopmental outcomes in term babies with hyperbilirubinemia. Indian J Pediatr 2012; 79: 202-6.
332. Seidman DS, Paz I, Stevenson DK, Laor A, Danon YL, Gale R.Neonatal hyperbilirubinemia and physical and cognitive perform- ance at 17 years of age. Pediatrics 1991; 88: 828-33.
333. Zhang L, Liu W, Tanswell AK, Luo X. The effects of bilirubin on evoked potentials and long-term potentiation in rat hippocampus in vivo. Pediatr Res 2003; 53: 939-44.
334. Hokkanen L, Launes J, Michelsson K. Adult neurobehavioral out-come of hyperbilirubinemia in full term neonates-a 30 year prospective follow-up study. Peer J 2014; 2: e294.
335. Gardener H, Spiegelman D, Buka SL. Perinatal and neonatal risk factors for autism: a comprehensive meta-analysis. Pediatrics 2011; 128: 344-55.
336. Maimburg RD, Bech BH, Vaeth M, Moller-Madsen B, Olsen J.Neonatal jaundice, autism, and other disorders of psychological de- velopment. Pediatrics 2010; 126: 872-8.
337. May-Benson TA, Koomar JA, Teasdale A. Incidence of pre-, peri-,and post-natal birth and developmental problems of children with sensory processing disorder and children with autism spectrum disorder. Front Integr Neurosci 2009; 3: 31.
338. Dalman C, Cullberg J. Neonatal hyperbilirubinaemia--a vulnerabil-ity factor for mental disorder? Acta Psychiatr Scand 1999; 100: 469-71.
339. Gordo AC, Falcao AS, Fernandes A, Brito MA, Silva RF, Brites D.Unconjugated bilirubin activates and damages microglia. J Neurosci Res 2006; 84: 194-201.
340. Fernandes A, Silva RF, Falcao AS, Brito MA, Brites D. Cytokine production, glutamate release and cell death in rat cultured astrocytes treated with unconjugated bilirubin and LPS. J Neuroimmunol 2004; 153: 64-75.
341. Barateiro A, Vaz AR, Silva SL, Fernandes A, Brites D. ER Stress,Mitochondrial dysfunction and calpain/JNK activation are involved in oligodendrocyte precursor cell death by unconjugated bilirubin. Neuromol Med 2012; 14(4): 285-302.
342. Rodrigues CM, Sola S, Brites D. Bilirubin induces apoptosis via the mitochondrial pathway in developing rat brain neurons. Hepatology 2002; 35: 1186-95.
343. Genc S, Genc K, Kumral A, Baskin H, Ozkan H. Bilirubin is cyto-toxic to rat oligodendrocytes in vitro. Brain Res 2003; 985: 135-41.
344. Fernandes A; Barateiro A; Falcao AS, et al. Astrocyte reactivity to unconjugated bilirubin requires TNF-alpha and IL-1beta receptor signaling pathways. Glia 2011; 59: 14-25.
345. Fernandes A, Falcao AS, Silva RF, et al. Inflammatory signaling pathways involved in astroglial activation by unconjugated bilirubin. J Neurochem 2006; 96: 1667-79.
346. Silva SL, Vaz AR, Barateiro A, et al. Features of bilirubin-induced reactive microglia: from phagocytosis to inflammation. Neurobiol Dis 2010; 40: 663-75.
347. Barateiro A, Miron VE, Santos SD, et al. Unconjugated bilirubin restricts oligodendrocyte differentiation and axonal myelination. Mol Neurobiol 2013; 47: 632-44.
348. Barateiro A, Domingues HS, Fernandes A, Relvas JB, Brites D.Rat cerebellar slice cultures exposed to bilirubin evidence reactive gliosis, excitotoxicity and impaired myelinogenesis that Is pre-vented by AMPA and TNF-alpha inhibitors. Mol Neurobiol 2014; 49: 424-39.
349. Brito MA, Zurolo E, Pereira P, Barroso C, Aronica E, Brites D. Cerebellar axon/myelin loss, angiogenic sprouting, and neuronal increase of vascular endothelial growth factor in a preterm infant with kernicterus. J Child Neurol 2012; 27: 615-24.
350. Ahdab-Barmada M, Moossy J. The neuropathology of kernicterus in the premature neonate: diagnostic problems. J Neuropathol ExpNeurol 1984; 43: 45-56.
351. Gkoltsiou K, Tzoufi M, Counsell S, Rutherford M, Cowan F. Serial brain MRI and ultrasound findings: relation to gestational age, bili-rubin level, neonatal neurologic status and neurodevelopmental outcome in infants at risk of kernicterus. Early Hum Dev 2008; 84: 829-38.
352. Gurba PE, Zand R. Bilirubin binding to myelin basic protein, his- tones and its inhibition in vitro of cerebellar protein synthesis. Bio-chem Biophys Res Commun 1974; 58: 1142-7.
353. Hansen T, Tommarello S, Allen J. Subcellular localization of bilirubin in rat brain after in vivo i.v. administration of [3H]bilirubin. Pediatr Res 2001; 49: 203-7.
354. Chen HC, Wang CH, Tsan KW, Chen YC. An electron microscopic and adioautographic study on experimental kernicterus. II.Bilirubin movement within neurons and release of waste products via astroglia. Am J Pathol 1971; 64: 45-66.
355. Jew JY, Williams TH. Ultrastructural aspects of bilirubin encepha- lopathy in cochlear nuclei of the Gunn rat. J Anat 1977; 124: 599-614.
356. Henry LP, Amminger GP, Harris MG, et al. The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission. J Clin Psychiatry 2010; 71: 716-28.
357. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30: 67-76.
358. Foussias G, Remington G. Negative symptoms in schizophrenia:avolition and Occam's razor. Schizophr Bull 2010; 36: 359-69.
359. Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006; 32: 200-2.
360. Grima G, Benz B, Parpura V, Cuenod M, Do KQ. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res 2003; 62: 213-24.
361. Miyaoka T, Seno H, Itoga M, Iijima M, Inagaki T, Horiguchi J.Schizophrenia-associated idiopathic unconjugated hyperbiliru- binemia (Gilbert's syndrome). J Clin Psychiatry 2000; 61: 868-71.
362. Miyaoka T, Seno H, Itoga M, Iijima M, Inagaki T, Horiguchi J.Schizophrenia-associated idiopathic unconjugated hyperbiliru- binemia (Gilbert's syndrome). J Clin Psychiatry 2000; 61: 868-71.
363. Swerdlow NR. Integrative circuit models and their implications for the pathophysiologies and treatments of the schizophrenias. Curr Top Behav Neurosci 2010; 4: 555-83.
364. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009; 35: 528-48.
365. Daskalakis ZJ, Christensen BK, Fitzgerald PB, Chen R. Dysfunc-tional neural plasticity in patients with schizophrenia. Arch Gen Psychiatry 2008; 65: 378-85.
366. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expres-sion, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40-68.
367. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dy-sconnection in schizophrenia. Biol Psychiatry 2006; 59: 929-39.
368. Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophre-nia: from abnormal synaptic plasticity to failures of self- monitoring. Schizophr Bull 2009; 35: 509-27.
369. Lewis DA, Sweet RA. Schizophrenia from a neural circuitry per-spective: advancing toward rational pharmacological therapies. J Clin Invest 2009; 119: 706-16.
370. Smith MJ, Wang L, Cronenwett W, Mamah D, Barch DM, Cser-nansky JG. Thalamic morphology in schizophrenia and schizoaf- fective disorder. J Psychiatr Res 2011; 45: 378-85.
371. Volk DW, Lewis DA. Prefrontal cortical circuits in schizophrenia. Curr Top Behav Neurosci 2010; 4: 485-508.
372. Benes FM. Neural circuitry models of schizophrenia: is it dopa-mine, GABA, glutamate, or something else? Biol Psychiatry 2009; 65: 1003-5.
373. Dorph-Petersen KA, Pierri JN, Wu Q, Sampson AR, Lewis DA.Primary visual cortex volume and total neuron number are reduced in schizophrenia. J Comp Neurol 2007; 501: 290-301.
374. Dorph-Petersen KA, Delevich KM, Marcsisin MJ, et al. Pyramidal neuron number in layer 3 of primary auditory cortex of subjects with schizophrenia. Brain Res 2009; 1285: 42-57.
375. Simpson EH, Kellendonk C, Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 2010; 65: 585-96.
376. Smiley JF, Rosoklija G, Mancevski B, et al. Hemispheric compari-sons of neuron density in the planum temporale of schizophrenia and nonpsychiatric brains. Psychiatry Res 2011; 192: 1-11.
377. Featherstone RE, Kapur S, Fletcher PJ. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1556-71.
378. Lisman JE; Coyle JT; Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31: 234-42.
379. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349-52.
380. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunc-tion model of schizophrenia. J Psychiatr Res 1999; 33: 523-33.
381. Mandl RC; Rais M; van Baal GC, et al. Altered white matter con-nectivity in never-medicated patients with schizophrenia. Hum Brain Mapp 2013; 34: 2353-65.
382. Thaker GK. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr Bull 2008; 34: 760-73.
383. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci 2008; 31: 361-70.
384. Takahashi N, Sakurai T, Davis KL, Buxbaum JD. Linking oli-godendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog Neurobiol 2011; 93: 13-24.
385. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophrenia Res 2004; 67: 269-75.
386. Tkachev D, Mimmack ML, Ryan MM, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362: 798-805.
387. Hakak Y, Walker JR, Li C, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001; 98: 4746-51.
388. Matthews PR, Eastwood SL, Harrison PJ. Reduced myelin basic protein and actin-related gene expression in visual cortex in schizophrenia. PloS one 2012; 7: e38211.
389. Roussos P, Katsel P, Davis KL, et al. Molecular and genetic evidence for abnormalities in the nodes of Ranvier in schizophrenia. Arch Gen Psychiatry 2012; 69: 7-15.
390. Cruz DA, Weaver CL, Lovallo EM, Melchitzky DS, Lewis DA. Selective alterations in postsynaptic markers of chandelier cell in- puts to cortical pyramidal neurons in subjects with schizophrenia. Neuropsychopharmacology 2009; 34: 2112-24.
391. Heimer L. Basal forebrain in the context of schizophrenia. Brain Res Brain Res Rev 2000; 31: 205-35.
392. Kanaan RA, Kim JS, Kaufmann WE, Pearlson GD, Barker GJ, McGuire PK. Diffusion tensor imaging in schizophrenia. Biol Psy- chiatry 2005; 58: 921-9.
393. Kubicki M, Park H, Westin CF, et al. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage 2005; 26: 1109-18.
394. Kyriakopoulos M, Frangou S. Recent diffusion tensor imaging findings in early stages of schizophrenia. Curr Opin Psychiatry 2009; 22: 168-76.
395. Ellison-Wright I, Bullmore E. Anatomy of bipolar disorder and schizophrenia: Ametaanalysis. Schizophr Res 2010; 117: 12.
396. Zhang R; He J; Zhu S, et al. Myelination deficit in a phencyclidine-induced neurodevelopmental model of schizophrenia. Brain Res 2012; 1469: 136-43.
397. Hof PR, Haroutunian V, Friedrich VL, Jr., et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 2003; 53: 1075-85.
398. Stark AK, Uylings HB, Sanz-Arigita E, Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry 2004; 161: 882-8.
399. Byne W, Tatusov A, Yiannoulos G, Vong GS, Marcus S. Effects of mental illness and aging in two thalamic nuclei. Schizophr Res 2008; 106: 172-81.
400. Uranova N, Orlovskaya D, Vikhreva O, et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001;55: 597-610.
401. Uranova NA, Vostrikov VM, Vikhreva OV, Zimina IS, Kolomeets NS, Orlovskaya DD. The role of oligodendrocyte pathology in schizophrenia. Int J Neuropsychopharmacol 2007; 10: 537-45.
402. Kyriakopoulos M, Bargiotas T, Barker GJ, Frangou S. Diffusiontensor imaging in schizophrenia. Eur Psychiatry 2008; 23: 255-73.
403. Hoistad M, Segal D, Takahashi N, Sakurai T, Buxbaum JD, Hof PR. Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Front Neuroanat 2009; 3: 9.
404. Koch-Henriksen N, Sorensen PS. The changing demographic pat- tern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9:520-32.
405. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain J Neurol 2004; 127: 1463-78.
406. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002; 104: 182-91.
407. Baranzini SE. The genetics of autoimmune diseases: a networked perspective. Curr Opin Immunol 2009; 21: 596-605.
408. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Scle-rosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
409. Arnett PA. Does cognitive reserve apply to multiple sclerosis? Neurology 2010; 74: 1934-5.
410. Rejdak K, Jackson S, Giovannoni G. Multiple sclerosis: a practical overview for clinicians. Br Med Bull 2010; 95: 79-104.
411. Bashir K, Whitaker JN. Clinical and laboratory features of primary progressive and secondary progressive MS. Neurology 1999; 53:765-71.
412. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol 2008; 7: 852-8.
413. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-17.
414. Wootla B, Eriguchi M, Rodriguez M. Is multiple sclerosis an auto- immune disease? Autoimmune Dis 2012; 2012: 969657.
415. Pette M, Fujita K, Wilkinson D, et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the con-text of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci USA 1990; 87: 7968-72.
416. Valli A, Sette A, Kappos L, et al. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class IImolecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 1993; 91: 616-28.
417. Greer JM, Csurhes PA, Cameron KD, McCombe PA, Good MF, Pender MP. Increased immunoreactivity to two overlapping pep-tides of myelin proteolipid protein in multiple sclerosis. Br J Neu- rol 1997; 120 (Pt 8): 1447-60.
418. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells spe-cific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179: 973-84.
419. Hohlfeld R. 'Gimme five': future challenges in multiple sclerosis. ECTRIMS Lecture 2009. Multiple Sclerosis 2010; 16: 3-14.
420. O'Connor KC, Appel H, Bregoli L, et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005; 175: 1974-82.
421. Lindner M, Thummler K, Arthur A, et al. Fibroblast growth factor signalling in multiple sclerosis: inhibition of myelination and in-duction of pro-inflammatory environment by FGF9. Brain 2015; 138: 1875-93.
422. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120 (Pt 3): 393-9.
423. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-12.
424. Tallantyre EC, Bo L, Al-Rawashdeh O, et al. Clinico-pathological evidence that axonal loss underlies disability in progressive multi- ple sclerosis. Multiple Sclerosis 2010; 16: 406-11.
425. Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Wax-man SG. Molecular changes in neurons in multiple sclerosis: al- tered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci USA 2004; 101: 8168-73.
426. Coman I, Aigrot MS, Seilhean D, et al. Nodal, paranodal and jux-taparanodal axonal proteins during demyelination and remyelina- tion in multiple sclerosis. Brain 2006; 129: 3186-95.
427. Craner MJ, Lo AC, Black JA, Waxman SG. Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination. Brain 2003; 126: 1552-61.
428. Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007; 204: 2363-72.
429. Wolswijk G, Balesar R. Changes in the expression and localization of the paranodal protein Caspr on axons in chronic multiple sclerosis. Brain 2003; 126: 1638-49.
430. Howell OW, Palser A, Polito A, et al. Disruption of neurofascin localization reveals early changes preceding demyelination and re- myelination in multiple sclerosis. Brain 2006; 129: 3173-85.
431. Maier O, Baron W, Hoekstra D. Reduced raft-association of NF155 in active MS-lesions is accompanied by the disruption of the paranodal junction. Glia 2007; 55: 885-95.
432. Medana I, Martinic MA, Wekerle H, Neumann H. Transection of major histocompatibility complex class I-induced neurites by cyto- toxic T lymphocytes. Am J Pathol 2001; 159: 809-15.
433. Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lym-phocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002; 25: 313-9.
434. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclero-sis. Lancet Neurol 2002; 1: 232-41.
435. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Annl Neurol 2001; 50: 169-80.
436. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic reso- nance spectroscopy at 3 T. Brain 2005; 128: 1016-25.
437. Mahad DJ, Ziabreva I, Campbell G, et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009; 132: 1161-74.
438. Hagberg H, Gressens P, Mallard C. Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric dis- ease in children and adults. Ann Neurol 2012; 71: 444-57.
439. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP.The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63-75 e2.
440. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer'sdisease: occurrence, determinants, and strategies toward interven- tion. Dialogues Clin Neurosci 2009; 11: 111-28.
441. USDoHaH S. National Plan to Address Alzheimer’s Disease: 2013Update2013. Available from: http://aspe.hhs.gov/daltcp/napa/ NatlPlan2013.pdf.
442. Strydom A, Chan T, King M, Hassiotis A, Livingston G. Incidenceof dementia in older adults with intellectual disabilities. Res Develop Disabil 2013; 34: 1881-5.
443. de la Torre JC. Alzheimer's disease is incurable but preventable. JAlzheimer's Dis 2010; 20: 861-70.
444. Du H, Guo L, Yan SS. Synaptic mitochondrial pathology in Alz-heimer's disease. Antioxidants Redox Signal 2012; 16: 1467-75.
445. Zambrano CA, Egana JT, Nunez MT, Maccioni RB, Gonzalez-Billault C. Oxidative stress promotes tau dephosphorylation in neuronal cells: the roles of cdk5 and PP1. Free Radic Biol Med 2004; 36: 1393-402.
446. Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. Metals andamyloid-beta in Alzheimer's disease. Int J Exp Pathol 2005; 86: 147-59.
447. Reitz C. Dyslipidemia and the risk of Alzheimer's disease. Curr Atherosclerosis Reports 2013; 15: 307.
448. Zerovnik E. Protein conformational pathology in Alzheimer's and other neurodegenerative diseases; new targets for therapy. Curr Alzheimer Res 2010; 7: 74-83.
449. Morales I, Guzman-Martinez L, Cerda-Troncoso C, Farias GA, Maccioni RB. Neuroinflammation in the pathogenesis of Alz- heimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci 2014; 8: 112.
450. Meraz-Rios MA, Lira-De Leon KI, Campos-Pena V, De Anda-Hernandez MA, Mena-Lopez R. Tau oligomers and aggregation in Alzheimer's disease. J Neurochem 2010; 112: 1353-67.
451. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004; 6: 1054-61.
452. von Bernhardi R, Ramirez G. Microglia-astrocyte interaction in Alzheimer's disease: friends or foes for the nervous system? Biol Res 2001; 34: 123-8.
453. von Bernhardi R, Eugenin J. Microglial reactivity to beta-amyloid is modulated by astrocytes and proinflammatory factors. Brain Res 2004; 1025: 186-93.
454. Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent)rather than activated microglial cells are associated with tau pa- thology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 2009; 118: 475-85.
455. Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ. Early oligodendrocyte/myelin pathology in Alz- heimer's disease mice constitutes a novel therapeutic target. Am J Pathol 2010; 177: 1422-35.
456. Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ. Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 2009; 57: 54-65.
457. Bartzokis G, Lu PH, Mintz J. Human brain myelination and amy-loid beta deposition in Alzheimer's disease. Alzheimers Dement 2007; 3: 122-5.
458. Goedert M. Neuronal localization of amyloid beta protein precursor mRNA in normal human brain and in Alzheimer's disease. EMBO J 1987; 6: 3627-32.
459. Mita S, Schon EA, Herbert J. Widespread expression of amyloid beta-protein precursor gene in rat brain. Am J Pathol 1989; 134: 1253-61.
460. Palacios G, Palacios JM, Mengod G, Frey P. Beta-amyloid precur-sor protein localization in the Golgi apparatus in neurons and oligodendrocytes. An immunocytochemical structural and ultrastruc- tural study in normal and axotomized neurons. Brain Res Mol Brain Res 1992; 15: 195-206.
461. Skaper SD, Evans NA, Evans NA, Rosin C, Facci L, Richardson JC. Oligodendrocytes are a novel source of amyloid peptide gen- eration. Neurochem Res 2009; 34: 2243-50.
462. Lee JT, Xu J, Lee JM, et al. Amyloid-beta peptide induces oli-godendrocyte death by activating the neutral sphingomyelinaseceramide pathway. J Cell Biol 2004; 164: 123-31.
463. Roth AD, Ramirez G, Alarcon R, Von Bernhardi R. Oligodendro-cytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. Biol Res 2005; 38: 381-7.
464. Subasinghe S, Unabia S, Barrow CJ, Mok SS, Aguilar MI, Small DH. Cholesterol is necessary both for the toxic effect of Abeta pep- tides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes. J Neurochem 2003; 84: 471-9.
465. Kobayashi K, Hayashi M, Nakano H, et al. Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer's disease. Neuropathol Appl Neurobiol 2002; 28: 238-51.
466. Roher AE, Weiss N, Kokjohn TA, et al. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 2002; 41: 11080-90.
467. Tanaka F, Kachi T, Yamada T, Sobue G. Auditory and visual event-related potentials and flash visual evoked potentials in Alz- heimer's disease: correlations with Mini-Mental State Examination and Raven's Coloured Progressive Matrices. J Neurol Sci 1998; 156: 83-8.
468. Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cum-mings JL. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in ag- ing and Alzheimer's disease. Neurobiol Aging 2004; 25: 843-51.
469. Sjobeck M, Haglund M, Englund E. Decreasing myelin density reflected increasing white matter pathology in Alzheimer's disease--a neuropathological study. Int J Geriatr Psychiatry 2005; 20: 919-26.
470. Svennerholm L, Gottfries CG. Membrane lipids, selectively dimin-ished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem 1994; 62: 1039-47.
471. Alzheimer A, Forstl H, Levy R. On certain peculiar diseases of old age. History Psychiatry 1991; 2: 71-101.
472. Lee DY, Fletcher E, Martinez O, et al. Regional pattern of white matter microstructural changes in normal aging, MCI, and AD. Neurology 2009; 73: 1722-8.
473. Bartzokis G, Cummings JL, Sultzer D, Henderson VW, Nuechterlein KH, Mintz J. White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch Neurol 2003; 60: 393-8.
474. Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G. Decreased brain levels of 2',3'-cyclic nucleotide-3'-phosphodiesterase in Down syndrome and Alzheimer's disease. Neurobiol Aging 2001; 22: 547-53.
475. Hampel H, Teipel SJ, Alexander GE, et al. Corpus callosum atro-phy is a possible indicator of region- and cell type-specific neuronal degeneration in Alzheimer disease: a magnetic resonance im- aging analysis. Arch Neurol 1998; 55: 193-8.
476. Zhan X, Jickling GC, Ander BP, et al. Myelin injury and degraded myelin vesicles in Alzheimer's disease. Curr Alzheimer Res 2014; 11: 232-8.
477. Sun X, Wu Y, Gu M, Zhang Y. miR-342-5p decreases ankyrin G levels in Alzheimer's disease transgenic mouse models. Cell reports 2014; 6: 264-70.
478. Martisova E, Aisa B, Guerenu G, Ramirez MJ. Effects of earlymaternal separation on biobehavioral and neuropathological mark- ers of Alzheimer's disease in adult male rats. Curr Alzheimer Res 2013; 10: 420-32.
479. Cunningham C, Hennessy E. Co-morbidity and systemic inflamma-tion as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. Alzheimer's Res Ther 2015; 7: 33.